Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
    Journal Article

    Hobbs, G. S.; Hanasoge Somasundara, A. V.; Kleppe, M.; Litvin, R.; Arcila, M.; Ahn, J.; McKenney, A. S.; Knapp, K.; Ptashkin, R.; Weinstein, H.; more...
    Haematologica (2018)

    Fulltext@MSK | Save
  • Patrones de cambio de los inhibidores de la tirosina cinasa BCR-ABL1 en pacientes con LMC en fase crónica en la práctica clínica rutinaria estudio simplicity
    Meeting Abstract

    Encinas, M. P.; Goldberg, S. L.; Michallet, M.; Hehlmann, R.; Zyczynski, T.; Foreman, A.; Calimlim, B.; Paquette, R.; Simonsson, B.; Gambacorti Passerini, C.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Bosutinib (BOS) Vs Imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE Trial
    Meeting Abstract

    Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; Hochhaus, A.; more...
    Haematologica (2017)

    Fulltext@MSK | Save
  • Symptom burden, palliative care needs, and patient-provider communication among chronic myeloid leukemia survivors
    Meeting Abstract

    Zaleta, A. K.; Miller, M. F.; Johnson, J.; McManus, S.; Karten, C.; Mauro, M. J.; Buzaglo, J. S.
    Blood (2017)

    Fulltext@MSK | Save
  • Dasatinib discontinuation in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) and stable deep molecular response (DASFREE)
    Meeting Abstract

    Shah, N. P.; Gutiérrez, J. V. G.; Jiménez-Velasco, A.; Larson, S. M.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M.; Gómez-Casares, M. T.; Pane, F.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Results from ENESTgoal: A phase 2 study of treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) who switched from imatinib to nilotinib
    Meeting Abstract

    Ritchie, E. K.; Catchatourian, R.; Klisovic, R. B.; Pinilla-Ibarz, J.; Deininger, M. W.; Erba, H. P.; Radich, J. P.; Savona, M. R.; Dautaj, I.; Purkayastha, D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Bosutinib in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, and hematological safety characterization in the BFORE trial
    Meeting Abstract

    Mauro, M. J.; Gambacorti-Passerini, C.; Deininger, M. W.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutiérrez, V. G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: Results by 3-month BCR-ABL1 transcript level
    Meeting Abstract

    Hochhaus, A.; Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia (CML) in the BFORE trial: 18 month follow-up
    Meeting Abstract

    Gambacorti-Passerini, C.; Deininger, M. W.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Dyagil, I.; Glushko, N.; Milojkovic, D.; le Coutre, P. D.; Gutierrez, V. G.; more...
    Blood (2017)

    Fulltext@MSK | Save